1,892 patient study shows dramatic drop in infection in total joint surgery1
SKILLMAN, NEW JERSEY (October 1, 2012) - A new study looking at infections following joint replacement surgery finds a 78 percent decrease in joint infections when AQUACEL® Ag SURGICAL cover dressing was used.1 The results were presented at a ConvaTec-sponsored webcast on the global impact of deadly wound infections and the need to reduce the risk to patients last week in Washington, DC.
Even as joint replacement surgery becomes more commonplace, the incidence of postoperative infection, known as periprosthetic joint infection (PJI), has frustrated doctors and patients, resulting in longer hospital stays and higher costs. The study found that the infection rate for total joint replacement patients dropped to 0.4 percent when AQUACEL® Ag SURGICAL cover dressing was used as compared to 1.8 percent when gauze dressing was used.1
In a study published in The Journal of the American Medical Association just this week, it was noted that approximately 600,000 total knee replacement surgeries are done in the United States each year at the cost of approximately $15,000 per procedure. The authors noted that, with the volume of total knee replacements increasing over the past 20 years, the number of hospital re-admission rates and infection complications also increased.2
These dangerous infections following knee and hip surgery can be costly - to the patient, the hospital and the payor system. The increase in expenses associated with infection related to knee or hip surgery can cost $68,0003 and the postoperative hospital stay is lengthened by seven to 10 days with additional surgeries often needed.4
"Joint infection following knee or hip replacement is one of the most challenging complications we manage, not only increasing healthcare costs, but causing additional trauma and emotional challenges. AQUACEL® Ag SURGICAL cover dressing has been shown to play a vital role in reducing these risks," explains Peter F. Sharkey, MD, Professor, Orthopaedic Surgery, Jefferson Medical College, Rothman Institute, author of the data.
The retrospective study included data collected at Riddle Memorial Hospital, part of Main Line Health in Media, PA and evaluated the incidence of joint infection in 1,892 patients undergoing total joint repair. Patients received either AQUACEL® Ag SURGICAL cover dressing or standard gauze dressing. Each dressing was applied to the surgical site in the operating room and kept for 5 days postoperatively. The decision to switch to applying the AQUACEL® Ag SURGICAL cover dressing to surgical sites was part of the multimodal approach used at Riddle Hospital.1
AQUACEL® Ag SURGICAL cover dressing combines a unique Hydrofiber® Technology with skin friendly hydrocolloid technology, supported by evidence showing significant reduction in the incidence of superficial surgical site infection (SSI), skin blistering and delayed discharge compared to Mepore™ dressing covering AQUACEL dressing.5,6 The unique construction provides a waterproof, viral and bacterial barrier that allows for flexibility and extensibility during body movement.
The dressing also provides "on demand" broad-spectrum antimicrobial activity as demonstrated in vitro.7,8 AQUACEL® Ag dressings provide rapid and sustained antimicrobial activity, killing a broad spectrum of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), within 30 minutes of exposure to the dressing,7 for up to 7 days,8 as demonstrated in an in vitro wound model.
The dressings are available in five sizes for incisions from 4cm to 27cm in length. For more information please call 800-422-8811.
ConvaTec is the only company to offer wound dressings with Hydrofiber® Technology that gel on contact with fluid, providing clinicians and patients with substantial wound care benefits. Used for a wide range of moderate to highly exuding chronic and acute wounds, including surgical, trauma and burn wounds, AQUACEL® and AQUACEL® Ag dressings are soft, absorbent, non-woven wound dressings available in a variety of shapes, sizes and formats, including foam. As demonstrated time and again in a number of in vitro studies, this unique gelling action enables the dressings to lock in exudate and its harmful components7-11 and micro-contour closely to a simulated wound bed5.
ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support healthcare professionals from the hospital to the community health setting.
Hydrofiber and AQUACEL are registered trademarks of ConvaTec Inc.
Mepore is a registered trademark of Molnlycke Health Care
© 2012 ConvaTec Inc.